Advertisement · 728 × 90
#
Hashtag
#PostTest
Advertisement · 728 × 90
Integrity CE Learn more about the

#PostTest Q2️⃣ #TumorBoardTuesday

🧐A 75yo♀️w/ ER+/HER2- PIK3CA+ mBC starts 2L Tx w/alpelisib + fulvestrant. Baseline A1C = 6.1 & BMI = 33. What steps can limit risk for severe hyperglycemia❓

1) Labs QW x 2, then Qmonth
2) Baseline A1C, then Q3 months
3) Consider metformin premed
4) All of the above

0 0 1 0

#PostTest Q1️⃣ #TumorBoardTuesday

🤔What 2L Tx would you offer a 45yo♀️w/ ER+/HER2- mBC and an AKT mutation on 🧪liquid biopsy after progression at cycle 47 of ribociclib ➕ AI/OFS❓

1) Capecitabine monotherapy
2) Capivasertib + fulvestrant
3) Elacestrant monotherapy
4) Everolimus + fulvestrant

0 0 1 0
Preview
2024 Tumor Board Tuesday Evaluation Take this survey powered by surveymonkey.com. Create your own surveys for free.

#PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com/TBTeval24
👉🏽ALL CME🔗 integrityce.com/TBT2024

1 0 1 0

#PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com/TBT2024

🧐 Which of the following would you select for a 78-year-old man w/ mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/abraxane❓
1) FOLFIRINOX
2) Regorafenib trial
3) CLDN18.2 BiTe trial
4) Pembrolizumab

3 2 2 0

#PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com/TBTeval24
👉🏽ALL CME🔗 integrityce.com/TBT2024

🤔What percentage of pancreatic adenocarcinoma cases typically express Claudin 18.2?
1) 30%
2) 50%
3) 70%
4) 90%

3 2 1 0
Preview
Tumor Board Tuesday 2024 - Integrity CE Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice applicat...

#PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com/TBT2024

Which is likely to be optimal for HR+ mBC that progresses after 1Y of 1L ribociclib + AI and harbors an ESR1 Y537S mutation?
Abemaciclib + fulvestrant
Imlunestrant + abemaciclib
Elacestrant
Capivasertib + fulvestrant

3 2 0 0
Preview
2024 Tumor Board Tuesday Evaluation Take this survey powered by surveymonkey.com. Create your own surveys for free.

#PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com/TBTeval24
👉🏽ALL CME🔗 integrityce.com/TBT2024

Per INAVO120 data in ET-refractory, PIK3CA+ HR+ la/mBC, adding inavolisib to palbociclib + fulvestrant improved mPFS to:
9 months
12 months
15 months
18 months

3 2 1 0

#PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com/TBT2024

🧐 Which neoadjuvant therapy would you select for stage 3B, PD-L1+ EGFR/ALK WT NSCLC ❓
A. Chemo
B. Immunotherapy
C. Chemo-immunotherapy
D. Alectinib

0 0 1 0

#PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com/TBTeval24
👉🏽ALL CME🔗 integrityce.com/TBT2024

🤔Which neoadj/adj sequence is likely best for a Pt with stage3B (T4N2) EGFR+ NSCLC, PD-L1=1%❓
A. Chemo-RT -> osi
B. Osi -> Adj Chemo -> osi
C. Adj Chemo-RT -> osi
D. Durva-Neoadj Chemo -> osi

0 0 1 0